{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T08:03:06Z","timestamp":1771401786452,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100021092","name":"University of Yamanashi","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100021092","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06818-3","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:04:45Z","timestamp":1768878285000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low serum albumin levels and the nongerminal center B-cell subtype according to the Hans algorithm as strong prognostic factors in\u2009\u2265\u200980-year-old patients with large B-cell lymphoma treated with rituximab-containing chemotherapy"],"prefix":"10.1007","volume":"105","author":[{"given":"Ichiro","family":"Kawashima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayato","family":"Nakadate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideto","family":"Hyuga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minori","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuma","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Yamanda-Koshiishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Kirito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"issue":"4","key":"6818_CR1","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3324\/haematol.2022.281407","volume":"108","author":"A Tucci","year":"2023","unstructured":"Tucci A, Merli F, Fabbri A et al (2023) Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL). Haematologica 108(4):1083\u20131091","journal-title":"Haematologica"},{"issue":"22","key":"6818_CR2","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1182\/bloodadvances.2021004777","volume":"5","author":"KT Isaksen","year":"2021","unstructured":"Isaksen KT, Mastroianni MA, Rinde M et al (2021) A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL. Blood Adv 5(22):4771\u20134782","journal-title":"Blood Adv"},{"issue":"11","key":"6818_CR3","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1200\/JCO.20.02666","volume":"39","author":"L Oberic","year":"2021","unstructured":"Oberic L, Peyrade F, Puyade M et al (2021) Subcutaneous rituximab-MiniCHOP compared with subcutaneous rituximab-MiniCHOP plus lenalidomide in diffuse large B-cell lymphoma for patients age 80 years or older. J Clin Oncol 39(11):1203\u20131213","journal-title":"J Clin Oncol"},{"issue":"5","key":"6818_CR4","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/ejh.14268","volume":"113","author":"ZG Dilbaz","year":"2024","unstructured":"Dilbaz ZG, Denker S, Ankermann C et al (2024) Comparison of R-CHOP-14 and R-mini-CHOP in older adults with diffuse large B-cell lymphoma-a retrospective multicenter cohort study. Eur J Haematol 113(5):675\u2013684","journal-title":"Eur J Haematol"},{"issue":"5","key":"6818_CR5","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","volume":"12","author":"F Peyrade","year":"2011","unstructured":"Peyrade F, Jardin F, Thieblemont C et al (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 12(5):460\u2013468","journal-title":"Lancet Oncol"},{"issue":"12","key":"6818_CR6","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.3324\/haematol.2011.050617","volume":"96","author":"S Mareschal","year":"2011","unstructured":"Mareschal S, Lanic H, Ruminy P et al (2011) The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica 96(12):1888\u20131890","journal-title":"Haematologica"},{"issue":"2","key":"6818_CR7","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.3324\/haematol.2011.057240","volume":"97","author":"U Thunberg","year":"2012","unstructured":"Thunberg U, Enblad G, Berglund M (2012) Classification of diffuse large B-cell lymphoma by immunohistochemistry demonstrates that elderly patients are more common in the non-GC subgroup and younger patients in the GC subgroup. Haematologica 97(2):e3 (author reply e4)","journal-title":"Haematologica"},{"issue":"7","key":"6818_CR8","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/ajh.26579","volume":"97","author":"L Malpica","year":"2022","unstructured":"Malpica L, Marques-Piubelli ML, Beltran BE et al (2022) EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management. Am J Hematol 97(7):951\u2013965","journal-title":"Am J Hematol"},{"issue":"5","key":"6818_CR9","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M et al (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109(5):1857\u20131861","journal-title":"Blood"},{"issue":"1","key":"6818_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jha2.61","volume":"1","author":"K Hohloch","year":"2020","unstructured":"Hohloch K, Ziepert M, Truemper L et al (2020) Low serum albumin is an independent risk factor in elderly patients with aggressive B-cell lymphoma: results from prospective trials of the German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group. EJHaem 1(1):181\u2013187","journal-title":"EJHaem"},{"issue":"8","key":"6818_CR11","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s00277-014-2031-2","volume":"93","author":"S Dalia","year":"2014","unstructured":"Dalia S, Chavez J, Little B et al (2014) Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era. Ann Hematol 93(8):1305\u20131312","journal-title":"Ann Hematol"},{"issue":"4","key":"6818_CR12","first-page":"767","volume":"70","author":"L Chen","year":"2023","unstructured":"Chen L, Pan L, Liu T (2023) Prognostic value of serum albumin level in patients with diffuse large B cell lymphoma. Acta Biochim Pol 70(4):767\u2013776","journal-title":"Acta Biochim Pol"},{"issue":"11","key":"6818_CR13","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1200\/JCO.20.02465","volume":"39","author":"F Merli","year":"2021","unstructured":"Merli F, Luminari S, Tucci A et al (2021) Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective elderly project of the Fondazione Italiana Linfomi. J Clin Oncol 39(11):1214\u20131222","journal-title":"J Clin Oncol"},{"issue":"1","key":"6818_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275\u2013282","journal-title":"Blood"},{"issue":"5","key":"6818_CR15","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579\u2013586","journal-title":"J Clin Oncol"},{"issue":"27","key":"6818_CR16","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068","journal-title":"J Clin Oncol"},{"issue":"3","key":"6818_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48(3):452\u2013458","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"6818_CR18","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1182\/bloodadvances.2021004665","volume":"5","author":"EJ Bataillard","year":"2021","unstructured":"Bataillard EJ, Cheah CY, Maurer MJ et al (2021) Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review. Blood Adv 5(9):2426\u20132437","journal-title":"Blood Adv"},{"issue":"2","key":"6818_CR19","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/ajh.27151","volume":"99","author":"D Al-Sarayfi","year":"2024","unstructured":"Al-Sarayfi D, Brink M, Chamuleau MED et al (2024) R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma: a propensity matched population-based study. Am J Hematol 99(2):216\u2013222","journal-title":"Am J Hematol"},{"issue":"6769","key":"6818_CR20","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769):503\u2013511","journal-title":"Nature"},{"issue":"4","key":"6818_CR21","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.leukres.2011.12.012","volume":"36","author":"JJ Castillo","year":"2012","unstructured":"Castillo JJ, Beltran BE, Song MK et al (2012) The hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res 36(4):413\u2013417","journal-title":"Leuk Res"},{"issue":"1","key":"6818_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4149\/neo_2013_010","volume":"60","author":"K Benesova","year":"2013","unstructured":"Benesova K, Forsterova K, Votavova H et al (2013) The Hans algorithm failed to predict outcome in patients with diffuse large B-cell lymphoma treated with rituximab. Neoplasma 60(1):68\u201373","journal-title":"Neoplasma"},{"issue":"2","key":"6818_CR23","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1200\/JCO.2002.20.2.494","volume":"20","author":"L Repetto","year":"2002","unstructured":"Repetto L, Fratino L, Audisio RA et al (2002) Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology study. J Clin Oncol 20(2):494\u2013502","journal-title":"J Clin Oncol"},{"key":"6818_CR24","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.leukres.2018.07.014","volume":"71","author":"SH Kim","year":"2018","unstructured":"Kim SH, Go SI, Seo J et al (2018) Prognostic impact of pretreatment albumin to globulin ratio in patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res 71:100\u2013105","journal-title":"Leuk Res"},{"issue":"1","key":"6818_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2023.2293514","volume":"29","author":"W Wu","year":"2024","unstructured":"Wu W, Miao L, Zhao L et al (2024) Prognostic value of lactate dehydrogenase, serum albumin and the lactate dehydrogenase\/albumin ratio in patients with diffuse large B-cell lymphoma. Hematology 29(1):2293514","journal-title":"Hematology"},{"issue":"1","key":"6818_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00277-016-2819-3","volume":"96","author":"Y Ochi","year":"2017","unstructured":"Ochi Y, Kazuma Y, Hiramoto N et al (2017) Utility of a simple prognostic stratification based on platelet counts and serum albumin levels in elderly patients with diffuse large B cell lymphoma. Ann Hematol 96(1):1\u20138","journal-title":"Ann Hematol"},{"issue":"22","key":"6818_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000042165","volume":"104","author":"T Cetintepe","year":"2025","unstructured":"Cetintepe T, Cetintepe L, Unal DK et al (2025) HALP score and GNRI: simple and powerful prognostic markers in diffuse large B-cell lymphoma. Medicine (Baltimore) 104(22):e42165","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"6818_CR28","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH et al (2022) Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 386(4):351\u2013363","journal-title":"N Engl J Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06818-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06818-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06818-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:03:37Z","timestamp":1771398217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06818-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["6818"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06818-3","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the University of Yamanashi (Approval No. 2357). In accordance with the committee\u2019s guidelines, informed consent was obtained using an opt-out approach. Information regarding the study was made publicly available through the university\u2019s website and\/or bulletin boards, and participants were given the opportunity to decline participation. All patient data were anonymized prior to analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}